Clinical trials: Immunochemotherapy
Non-Small Cell Lung Cancer
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
This study will review medical records from hospitals in Poland to describe the demographics and baseline clinical characteristics of adults with advanced non-small cell lung cancer who received first-line nivolumab plus…
- Trial name
- NCT07526961
- Testing
- Nivolumab + Ipilimumab + Chemotherapy
- Where
- Poland
- Volunteers
- 240 people
- Sponsor
- Bristol-Myers Squibb
Relapsed or Refractory Multiple Myeloma
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
- Trial name
- NCT01670994
- Testing
- ALT-801
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Altor BioScience
Gastric and Gastroesophageal Junction Adenocarcinoma
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
This randomized, multicenter, double-blind, phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab (AK104) and pulocimab (AK109) and paclitaxel compared with paclitaxel in patients with advanced…
- Trial name
- NCT06341335
- Testing
- cadonilimab, pulocimab, paclitaxel
- Where
- China
- Volunteers
- 506 people
- Sponsor
- Akeso
Leukemia
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.
- Trial name
- CLL-8 (NCT00281918)
- Testing
- Rituximab, Cyclophosphamide, Fludarabine Phosphate
- Where
- 162 sites in Australia, Austria and 9 more
- Volunteers
- 817 people
- Sponsor
- Hoffmann-La Roche
B-cell Lymphoma
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
To evaluate the efficacy and safety of TQB3702 tablets combined with immunochemotherapy for the treatment of B-cell lymphoma
- Trial name
- NCT06566586
- Testing
- TQB3702 tablets+Chemotherapy regimen
- Where
- 30 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lymphoma, Non-Hodgkin
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine [R-B] and rituximab in combination with a 4 drug combination of…
- Trial name
- CHRONOS-4 (NCT02626455)
- Testing
- Copanlisib (BAY80-6946), Rituximab, Cyclophosphamide
- Where
- 201 sites in United States, Australia and 33 more
- Volunteers
- 551 people
- Sponsor
- Bayer
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
- Trial name
- LOTIS 5 (NCT04384484)
- Testing
- Loncastuximab Tesirine, Rituximab, Gemcitabine
- Where
- 144 sites in United States, Argentina and 19 more
- Volunteers
- 440 people
- Sponsor
- ADC Therapeutics S.A.
Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab…
- Trial name
- NCT07098988
- Testing
- Visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2
- Where
- 51 sites in United States, Germany and 5 more
- Volunteers
- 107 people
- Sponsor
- CatalYm GmbH
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet…
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma
- Trial name
- VIRO-25 (NCT06463665)
- Testing
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
- Where
- 15 sites in United States
- Volunteers
- 142 people
- Sponsor
- Genelux Corporation
Non-Hodgkin's Lymphoma
A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab
This multicenter, randomized, open-label, parallel-group study will evaluate the efficacy and safety of subcutaneously administered rituximab in comparison with observation only as maintenance therapy in participants with…
- Trial name
- MabCute (NCT01461928)
- Testing
- Chemotherapy (Induction Period), Rituximab
- Where
- 180 sites in Albania, Argentina and 22 more
- Volunteers
- 692 people
- Sponsor
- Hoffmann-La Roche
Non Hodgkin Lymphoma, Breast Cancer
Patient Preference for Pegfilgrastim (Neulasta®) Application Forms
The study aims to compare two application forms (pre-filled syringe and On-body injector) of the same active drug (pegfilgrastim) in adult patients under chemotherapy regarding patient preference and health economics.
- Trial name
- CONVENIENCE (NCT03619993)
- Testing
- On-body injector, Pre-filled syringe
- Where
- 48 sites in Germany
- Volunteers
- 404 people
- Sponsor
- iOMEDICO AG
CLL/SLL
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
This is a global, multicenter, randomized, open-label, Phase III confirmatory study to investigate the efficacy and safety of Lisaftoclax (APG-2575) in combination with Acalabrutinib in patients with newly diagnosed CLL/SLL.
- Trial name
- NCT06319456
- Testing
- Lisaftoclax (APG-2575), Acalabrutinib, Fludarabine
- Where
- 10 sites in China
- Volunteers
- 344 people
- Sponsor
- Ascentage Pharma Group Inc.
Transitional Cell Carcinoma of Bladder, Urethra Cancer
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who…
- Conditions
- Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
- Trial name
- NCT01326871
- Testing
- Cisplatin, Gemcitabine, ALT-801
- Where
- 16 sites in United States
- Volunteers
- 68 people
- Sponsor
- Altor BioScience
Metastatic Cancer
A Phase 2 Trial for Patients With Metastatic Solid Cancer
This study seeks to estimate the potential efficacy of the study treatment, as well as the occurrence of adverse events.
- Trial name
- NCT04713371
- Testing
- Keytruda Injectable Product, Yervoy Injectable Product, Cytoxan
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Rampart Health, L.L.C.
Relapsed or Refractory Multiple Myeloma
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT02099539
- Testing
- N-803
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Altor BioScience
Diffuse Large B-cell Lymphoma
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease…
- Trial name
- NCT03677154
- Testing
- Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin
- Where
- 32 sites in United States, Israel and 4 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Follicular Lymphoma (FL), Non Hodgkin Lymphoma
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL…
- Conditions
- Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04745832
- Testing
- Zandelisib, Rituximab, Bendamustine
- Where
- 141 sites in United States, Australia and 17 more
- Volunteers
- 82 people
- Sponsor
- MEI Pharma, Inc.
Diffuse Large B-Cell Lymphoma
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
This Phase Ib/II study is a clinical trial to explore the efficacy and safety of BL-M08D1 for injection in combination with immunochemotherapy in patients with diffuse large B-cell lymphoma.
- Trial name
- NCT07818499
- Testing
- BL-M08D1, Rituximab, Gemcitabine Hydrochloride
- Where
- 2 sites in China
- Volunteers
- 204 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Diffuse Large B Cell Lymphoma
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
To explore the efficacy and safety of TQB2825 injection combined immunochemotherapy in subjects with untreated or R/R DLBCL. The efficacy evaluation indicators are objective response rate (ORR), complete response rate (CR…
- Trial name
- NCT06829771
- Testing
- TQB2825 injection +R-CHOP regimen, TQB2825 injection + GemOx
- Where
- 25 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05281471
- Testing
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Where
- 33 sites in United States
- Volunteers
- 186 people
- Sponsor
- Genelux Corporation